Cerevel Therapeutics Holdings, Inc. was an American biotechnology and pharmaceuticals company based in Cambridge, Massachusetts, focused on the development of novel therapies for mental and neurological illnesses.[1]
Cerevel was established in October 2018.[2] The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.[3][4]
In 2019, Cerevel appointed N. Anthony Coles as its chief executive officer.[5] In 2020, Coles led Cerevel's effort to raise $445 million for brain drugs, the third largest biotech public listing at that time (after Legend Biotech and Moderna).[6] In May 2023, Coles resigned from his position as CEO, yet retained his role as board chairman of Cerevel.[7]
In December 2023, American pharmaceutical company AbbVie announced its intention to acquire Cerevel for US$8.7billion.[8][9][10] The acquisition was completed in August 2024 with Cerevel becoming a subsidiary of Abbvie.[11][bettersourceneeded][12]
Pipeline
Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more.[13]
Notable Cerevel drugs and treatments at varying stages of development include:
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease.[19] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types.[1]
The company has stated its approach to neurotherapy development can be viewed as:
Development of treatment opportunities by precisely identifying and targeting the neurocircuitry that underlies a given neurological disease.[1]
Selective targeting of only the relevant receptor subtype(s) related to the physiology of the disease being treated. This has the impact of minimizing undesired off-target and side effects, while maximizing activity.[1]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.